Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$27.77
+0.45 (+1.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.1B · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.5B
P/E
14.1x
↓EV/EBITDA
3.6x
↓ROE
18.7%
↑Gross Margin
85.1%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.6%
FCF CAGR
+3.4%
FCF margin
54.9%
FCF / Net income
2.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.23B · net income $535.1M · FCF $1.22B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.23B | $2.23B | $2.13B | $2.48B | $2.34B |
| Net Income | $535.1M | $535.1M | $515.6M | $585.3M | $526.9M |
| EBITDA | $1.26B | $1.26B | $1.25B | $1.40B | $1.23B |
| EPS | 2.28 | 2.28 | 2.20 | 2.50 | 2.25 |
| Gross Margin | 85.1% | 85.1% | 83.8% | 86.4% | 78.6% |
| Operating Margin | 53.6% | 53.6% | 54.6% | 51.3% | 48.8% |
| Net Margin | 24.0% | 24.0% | 24.2% | 23.6% | 22.5% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | — | 0.00 |
| Current Ratio | 12.06 | 12.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.22B | $1.22B | $886.0M | $1.12B | $1.11B |
| Returns | |||||
| ROE | 18.7% | 18.7% | 17.7% | 19.6% | 20.4% |
| Valuation | |||||
| P/E | 14.10 | 14.10 | 11.74 | 11.89 | 19.40 |
| EV/EBITDA | 3.56 | 3.56 | 3.14 | 3.51 | 6.83 |
| P/B | 2.28 | 2.28 | 2.08 | 2.33 | 3.96 |
| Growth & Yield | |||||
| Revenue Growth | 4.4% | 4.4% | -14.1% | 6.1% | — |
| EPS Growth | 3.6% | 3.6% | -12.0% | 11.1% | — |
| Dividend Yield | 9.0% | 9.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
2.6%
EPS terminal req.
$2.46
Spread vs growth
1.0%
5Y implied EPS CAGR
5.5%
EPS terminal req.
$2.98
Spread vs growth
-1.9%
10Y implied EPS CAGR
7.7%
EPS terminal req.
$4.80
Spread vs growth
-4.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.8%
Start / end P/E
13.6x → 12.2x
EPS bridge
2.20 → 2.28
Residual
-0.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.